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Abstract  
Interferon lambda (IFNλ) is important for epidermal defence against viruses.  It is produced 
by, and acts on, keratinocytes, whereas fibroblasts were previously considered to be 
unresponsive to this type III IFN.  
Herein we report novel findings revealing cell type-specific differences in IFNλ signalling and 
function in skin resident cells. In dermal fibroblasts, IFNλ induces the expression of MxA, a 
potent antiviral factor, but not other interferon signature genes as it does in primary 
keratinocytes. In contrast to its effect on keratinocytes, IFNλ does not phosphorylate STAT1 
in fibroblasts, but instead activates MAPK. Accordingly, inhibition of MAPK activation (p38 
and p42/44) blocks expression of MxA protein in fibroblasts but not in keratinocytes. 
Functionally, IFNλ inhibited proliferation in keratinocytes but not in fibroblasts. Moreover, 
IFNλ upregulated the expression of TGFβ1-induced collagens in fibroblasts. Taken together, 
our findings identify primary human dermal fibroblasts as responder cells to IFNλ. Our study 
shows cutaneous cell type-specific IFN signalling and suggests that IFNλ, whilst important 
for epidermal anti-viral competence, may also have a regulatory role in the dermal 
compartment balancing type I IFN-induced inhibition of tissue repair processes. 
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Introduction   
Fibroblasts and keratinocytes are the main tissue cell types found in the dermis and 
epidermis respectively. While many recent studies have identified the immunological role of 
keratinocytes, the role of dermal fibroblasts in host defence and inflammatory diseases are 
only beginning to emerge. Furthermore,  dermal fibroblasts synthesise extracellular matrix 
including collagens (Xu et al., 2009) and thus play an important role in maintaining skin 
structure and wound healing. Interferon lambda (IFNλ) is a type III IFN comprising four 
members, IFNλ1 (IL-29), IFNλ2 (IL-28A), IFNλ3 (IL-28B) and IFNλ4 (Kotenko et al., 2003; 
Prokunina-Olsson et al., 2013; Sheppard et al., 2003).  IFNλ belongs to the IL-10 family of 
cytokines along with IL-10, IL-19, IL-20, IL-22, IL-24 and IL-26. IFNλ uses the heterologous 
receptor complex comprising IFNλR1 (also known as IL-28Rα1) and the ubiquitously 
expressed IL-10 receptor 2 (IL-10Rβ) which is also used by IL-10, IL-22 and IL-26 as a 
second receptor subunit (Kotenko et al., 2003; Sheppard et al., 2003). IFNλR1 is the 
signalling subunit and so its presence determines cellular responsiveness. Although IFNλ is 
structurally related to IL-10, it resembles type I IFNs in its antiviral and antiproliferative 
functions (Miknis et al., 2010). They both signal mainly through the recruitment and 
activation of members of the janus family of kinases, JAK1/TYK2 leading to the 
phosphorylation of signal transducer and activator of transcription (STAT) 1/2 and 
subsequently to induction of  a set of downstream genes known as IFN-stimulated genes 
(ISGs) such as Myxovirus protein A (MxA), Guanylate binding protein 1 (GBP-1), 2,5-
oligoadenylate synthetase (2,5-OAS) and IFN inducible protein 16 (IFI16) with potent 
antiviral activities (Ank et al., 2008; Sommereyns et al., 2008). Beyond JAK/STAT activation,  
type I IFNs have also been found to activate MAPK (p38 and ERK (p42/p44) MAPK) which 
allows for full activation of downstream ISGs (Nguyen et al., 2000; Uddin et al., 2000); and 
possibly downstream phosphorylation of STAT1 on serine 727 (Goh et al., 1999). 
Type I IFNs signal through membrane associated IFNAR1 and IFNAR2 (Lutfalla et al., 
1995). While the two subunits of IFNAR are present on all nucleated cell types, IFNλR1 is 
selectively expressed and functional in certain cell types only (Dickensheets et al., 2013; 
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Kotenko et al., 2003; Witte et al., 2009; Zahn et al., 2010). Witte et al. described the 
presence of IL-28Rα1 mRNA expression in human dermal fibroblasts. However, it was 
observed that these cells were unresponsive to IFNλ, and this was attributed to the very low 
expression level of the receptor in these cells (Lasfar et al., 2011; Witte et al., 2009).  
IFNλ is the main IFN produced by keratinocytes and production of varying amounts of this 
cytokine has been reported also in other cell types (Wolk et al., 2013; Yin et al., 2012; Zahn 
et al., 2010). Keratinocytes are susceptible to IFNλ1 and this cytokine substantially 
contributes to the antiviral competence of the human epidermis (Wolk et al., 2013). Apart 
from antiviral properties, both types I and III IFNs are known for their pro-apoptotic and anti-
proliferative activities (Abushahba et al., 2010; Steen and Gamero, 2010); which has also 
been reported for HaCaT keratinocyte cell lines (Maher et al., 2008). These activities have 
been linked to the ability of IFNs to phosphorylate STAT1 (Zitzmann et al., 2006). High 
expression of ISGs such as CXCL9, CXCL10, MxA and GBP-1 has been reported in 
interface dermatitis conditions such as cutaneous lupus erythematosus (CLE) and here 
increased expression is linked with disease severity (Naschberger et al., 2010; Wenzel et al., 
2005).  
In this study, we sought to understand if human dermal fibroblasts are responsive to IFNλ1 
through the activation of STAT1 and subsequent downstream induction of ISGs. We also 
wanted to understand the role of this cytokine in maintenance of skin integrity with regard to 
collagen expression and proliferation of skin resident cells. 
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Results 
IFNλR1 is expressed by human dermal fibroblasts 
The presence of low levels of IFNλR1 mRNA in human dermal fibroblasts has been reported 
(Witte et al., 2009). In order to confirm the expression of IFNλR1 in fibroblasts and to 
investigate its regulation, fibroblasts were stimulated for 4 or 16 hours for analysis of mRNA 
and protein expression, respectively. We found that IFNλR1 was expressed in human 
dermal fibroblasts and that it was upregulated in the presence of IFNα (Figure 1a-c). IFNλR1 
protein expression was also verified in fibroblasts using flow cytometry (data not shown). 
 
IFNλ induces significant expression of MxA in human dermal fibroblasts 
To investigate if IFNλR1 is functional in human dermal fibroblasts, cells were treated with 
rhIFNλ for 4 or 24 hours and mRNA expression of ISGs was quantified using qRT-PCR. 
rhIFNα was used as positive control to which dermal fibroblasts are known to respond. We 
found significant expression of MxA but not GBP-1 (Figure 2a-d) or other analysed ISGs 
such as CXCL9 and IFI-16 (data not shown) after 4 and 24 hours of IFNλ1 treatment. As 
expected, when compared to IFNλ1, IFNα induced significantly higher expression of MxA 
and GBP-1 after 4 hours of treatment (Figure 2a-d). However, while the expression of MxA 
remained high after 24 hours of treatment with IFNα, GBP-1 expression dropped significantly 
over this time period (Figure 2b/d). In fibroblasts, IFNα appeared to induce higher 
upregulation of MxA as compared to GBP-1 (Figure 2a-d). 
 
IFNα and IFNλ induce ISG expression in human primary keratinocytes 
We compared our findings on ISGs expression in fibroblasts with the expression pattern in 
human primary keratinocytes. The responsiveness of keratinocytes to both type I and III 
IFNs is well documented (Bachmann et al., 2013; Zahn et al., 2011; Zahn et al., 2010). We 
found that both IFNα and IFNλ1 induced significant mRNA expression of both MxA and 
GBP-1 with a higher induction of MxA as compared to GBP-1 (Figure 2e-h). Interestingly, we 
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observed a markedly different time kinetic for the ISG response to IFNα as compared to 
IFNλ1. Different to IFNα which showed a strong upregulation of the ISGs MxA and GBP-1 at 
6 hours, IFNλ1 stimulation resulted in a strong increase in MxA and GBP-1 expression 
between 6 and 24 hours. This suggests that IFNλ1 stimulation may result in more delayed 
and/or longer lasting effects (Figure 2e-h) as previously observed in hepatocytes (Bolen et 
al., 2014).  
 
IFNλ activates p38 and ERK MAPKs but not STAT1 (Tyr701) in human dermal 
fibroblasts 
Type I and III IFNs are known to activate the canonical JAK/STAT pathway to induce 
downstream gene expression. Having established that dermal fibroblasts respond to IFNλ1, 
we were interested in understanding their mechanism of action. To achieve this, dermal 
fibroblasts were treated with either IFNλ1 or IFNα for different time points and protein 
phosphorylation was determined using western blotting. As expected, IFNα-induced STAT1 
phosphorylation with maximal phosphorylation detected after 30 minutes of stimulation 
(Figure 3a). However, we failed to observe any STAT1 phosphorylation in IFNλ1 treated 
cells in any of the time points investigated. Various groups have reported that 
phosphorylation of p38 may be necessary for full activation of STAT1 dependent genes (Goh 
et al., 1999; Platanias, 2003; Uddin et al., 2000). We therefore investigated the ability of 
IFNλ1 to induce the phosphorylation of p38 in dermal fibroblasts and clearly found activation 
of this MAPK (Figure 3a). We confirmed that IFNα treatment resulted in p38 phosphorylation 
in addition to STAT1 phosphorylation (Figure 3a). Furthermore, we found that both IFNα and 
IFNλ1 induced phosphorylation of ERK, but not the Akt (p60) (data not shown) pathway in 
dermal fibroblasts. . As expected, we found that both IFNα and IFNλ1 induced STAT1 
phosphorylation in human primary keratinocytes (Figure 3b). However, we did not observe 
clear IFNλ dependent activation of either the p38 or ERK pathway upon treatment with IFNs 
(Figure 3b). 
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P38 and ERK inhibitors attenuate IFNλ1-induced MxA protein expression  
Based on our finding that IFNλ1 induces the activation of the p38 and ERK MAPKs, we 
sought to understand if these were responsible for the induction of MxA expression in dermal 
fibroblasts. To investigate this, fibroblasts were pretreated with p38 (10 (M SB203580) or 
ERK inhibitor (30 (M PD98059 or 10 (M U0126) for 1 hour before treatment with IFNλ1 or 
IFNα and analysis of mRNA or protein expression. Interestingly, our results showed that the 
expression of MxA was not regulated at the mRNA level by the MAPK inhibitors as we did 
not observe any significant difference in MxA mRNA expression in their presence or 
absence upon stimulation with cytokines (Figure 4a/b). However, at the protein level, the 
presence of either the p38 or ERK inhibitor abrogated IFNλ1 induced MxA protein production 
(Figure 4c). We did not observe a decrease in IFNα induced MxA protein production in 
fibroblasts in the presence of SB203580, PD98059 (not shown) or U0126 (Figure 4d). We 
also analysed whether MAPKs played a role in IFNλ1-induced MxA protein expression in 
human primary keratinocytes. When these cells were treated in the same manner as the 
fibroblasts, we failed to find a significant effect on IFNλ1 and IFNα induced MxA protein 
production in the context of p38 or ERK inhibition (Figure 4e). 
 
IFNλ enhances collagen expression in human dermal fibroblasts  
Dermal fibroblasts are essential for extracellular dermal matrix (ECM) homeostasis and also 
contribute to basement membrane formation and thus play an important role in repair 
processes. As conditions with high type I IFN expression can be linked to impaired healing 
responses, we investigated whether IFNλ1 had any influence on collagen expression. 
Fibroblasts were treated with IFNλ1, IFNα, TGFβ1 or a combination of IFN and TGFβ1. 
TGFβ1 was used as a control, given its well described stimulation of fibroblast proliferation 
and collagen synthesis. We measured Col1A1, Col3A1, Col4A2 and Col7A1 using qRT-
PCR. There was no difference in collagen expression after 6 hours of stimulation with these 
cytokines (data not shown). However, after 24 hours of treatment, TGFβ1 significantly 
induced the expression of these collagens. Combined treatment of cells with IFNλ1 and 
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TGFβ1 appeared to be at least additive as it resulted in a significantly higher expression of 
these collagens (except for Col3A1) than with either treatment alone (Figure 5a-d).  
 
IFNλ has potent anti-proliferative activity in primary keratinocytes but not in dermal 
fibroblasts  
The anti-proliferative effect of IFNλ1 on HaCaT keratinocyte cell lines has been described 
(Maher et al., 2008). We aimed to compare the effect of both IFNλ1 and IFNα on primary 
skin cells. Cultured human primary keratinocytes and dermal fibroblasts were stained with 
cell tracer dye and subsequently stimulated with either IFNλ or IFNα for 72 hours. As 
expected, both IFNs clearly reduced keratinocyte proliferation (Figure 6a/b). By contrast, we 
observed that IFNα but not IFNλ1 inhibits dermal fibroblast proliferation (Figure 6c/d). 
TGFβ1, known to induce fibroblast proliferation, was used as positive control (Figure 6c/d).  
We also investigated the effects of IFNλ1 and IFNα on “gap” closure in monolayer cultures of 
dermal fibroblasts to which both migration and proliferation of cells contribute. Confluent 
fibroblast cultures were “scratched” and stimulated with IFNs. Gap closure was monitored at 
time 0, 24 and 48 hours. We observed that IFNλ1 improved gap closure in fibroblasts while 
IFNα delayed gap closure after 48 hours of stimulation in comparison to the untreated cells 
(Figure S1).  
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Discussion 
Type I and III, innate IFNs were initially identified for their potent antiviral activities 
(MacMicking, 2012; Sadler and Williams, 2008). IFNs can regulate around 2000 different 
genes (Hertzog et al., 2011) and among the interferon stimulated genes,  MX1, which 
encodes for MxA, is highly inducible and one of the most potent anti-viral factors which has 
been shown to block the early replication events of different RNA and DNA viruses (Sadler 
and Williams, 2008). In addition, IFNs also have immunoregulatory, anti-proliferative and 
pro-apoptotic properties; they have been identified as potential anticancer drugs (Abushahba 
et al., 2010; Witte et al., 2010). However, they are also important mediators in the 
pathogenesis of autoimmune diseases such as cutaneous lupus erythematosus (Meyer, 
2009; Ronnblom and Eloranta, 2013). 
Type III IFN is the most recently described group of IFNs. Expression of their specific 
receptor was thought to be restricted mainly to epithelial cells (keratinocytes) and 
hepatocytes. There is, however, emerging evidence that IFNλR1 is also present and 
functional on hematopoietic cells, such as plasmocytoid dendritic cells, monocyte-derived 
macrophages, dendritic cells and T cells (Dai et al., 2009; Liu et al., 2011; Mennechet and 
Uze, 2006; Yin et al., 2012). Apart from the canonical JAK/STAT pathway for IFN signalling, 
there are reports identifying MAPKs as regulators of IFN downstream activities (Gough et al., 
2008; Uddin et al., 2000; van Boxel-Dezaire et al., 2006). The contribution and significance 
of different (non JAK) kinases activated in response to IFNs has been speculated before to 
contribute to cell-type and IFN subtype specific responses (van Boxel-Dezaire et al., 2006). 
However, so far, only few studies show data of IFNλ induced signalling in primary skin cells. 
The main novelty of our findings is that we show a distinct signalling and thus also functional 
response of primary human fibroblasts to IFNλ which is different from the response of these 
cells to type I IFN and which is clearly different from the response of epidermal cells. Indeed, 
keratinocytes show a similar signalling and functional response to both type I and type III 
IFNs which is characterised on the whole, a STAT1 dependent upregulation of a broad 
range of ISGs. Dermal fibroblasts have been considered to be unresponsive to this IFNλ 
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(Abushahba et al., 2010). We here challenge this view in showing that human fibroblasts 
respond to IFNλ1 treatment with significant expression of MxA mRNA and protein. In line 
with our findings, a recent study has reported the responsiveness of CMV infected foreskin 
fibroblast to IFNλ3 (Egli et al., 2014). It is well documented that types I and III IFNs induce 
similar sets of ISGs in many cell types (Ank et al., 2008; Sommereyns et al., 2008). 
However, in fibroblasts, we failed to observe significant expression of GBP-1 (Fig. 2) or other 
ISGs upon IFNλ1 treatment. The inability of IFNλ1 to activate STAT1 (Tyr701) in fibroblasts 
was unexpected as this is the known canonical pathway for the induction of downstream ISG 
genes. However, our findings on IFNλ1 induced activation of both p38 and ERK suggest that 
the MAPK pathway may be an alternative for the induction of MxA by IFNλ in fibroblasts. It 
has been suggested that IFNα-induced phosphorylation of MAPKs and STAT1 are 
independent of each other; however, they work in tandem to ensure full activation of ISGs (Li 
et al., 2004). It is interesting that despite these findings, inhibition of p38 and ERK in IFNα 
treated dermal fibroblasts did not result in significant downregulation of MxA protein 
expression; although we observed a slight reduction in MxA production by primary 
keratinocytes following inhibition of ERK but not p38. A more recent report has shown that 
both IFNλ1 and IFNα induce the activation of PI3K-AKT and Raf-MEK-ERK pathways in 
HepG2.2.15 cell lines (Chai et al., 2011). With regard to skin tissue cells (keratinocytes and 
fibroblasts), we could not observe AKT pathway activation.  Our proposed mechanism of 
IFNα and IFNλ1 signalling in dermal fibroblasts is shown in Figure S2. To our surprise, we 
failed to observe any significant regulatory effects of the MAPK inhibitors at the 
transcriptional level suggesting that p38 and ERK inhibition result in posttransciptional 
regulation of MxA. Mechanisms of mRNA translation of ISGs have been reviewed (Joshi et 
al., 2010). Both the p38 and p42/44 MAPKs can control the activation of eIF4E and other 
substrates of MAPK interacting protein kinases 1 and 2 (Mnk1 and 2) which influence 
translation initiation (Joshi et al., 2010). Mnk1 has been shown to prevent proteosomal 
degradation in response to growth factor stimulation in CHO-K1/COS1 cells (DaSilva et al., 
2006).Posttransriptional regulation of TNFα gene expression has been described in the 
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presence of p38 inhibitor (Clark et al., 2003). Future experiments will show the underlying 
mechanism of the posttranscriptional regulation observed for MxA in human dermal 
fibroblasts. In this study, we have confirmed previous report that human dermal fibroblasts 
express IFNλR1 (Witte et al., 2009) and that IFNα can upregulate its expression. The ability 
of IFNα to enhance the expression levels of IFNλR1 is evidence for a cross-talk between 
type I and type III IFNs. A similar effect of IFNα on IFNλR1 has been reported in primary 
human hepatocytes (Duong et al., 2014).  
TGFβ1 is well known to induce collagen expression in fibroblasts. Types I and III collagens 
are the main ECM components, type IV collagen is the main component of the lamina densa 
in the basement membrane zone and Type VII collagen is a component of the anchoring 
fibrils lying beneath the lamina densa at the dermal-epidermal junction (Tiedtke, 2007). We 
found that IFNλ1 potentiated the TGFβ-associated induction of collagen I, but not collagen 
type III, expression. IFNγ, a type II IFN has been shown to have an inhibitory effect on 
TGFβ1-induced ECM or collagen deposition in primary human lung (Eickelberg et al., 2001) 
and in human foreskin fibroblasts through the blocking of Smad signalling (Ghosh et al., 
2001). Of interest, keloid derived dermal fibroblasts seem non-responsive to this IFNγ 
dependent type I collagen regulation (Hasegawa et al., 2003).  Excessive secretion of type I 
collagen has been linked with disorganised fibre structure and hypertrophic scar formation, 
while a sufficient amount of type III collagen may prevent scar formation (Oliveira et al., 
2009). The net effect of IFNλ1 on cutaneous repair and healing responses is not clear yet 
and needs to be further investigated. The ability of IFNλ1 to upregulate the expression of 
type IV (Col4A2) and VII collagens (Col7A1) suggests that is may support basement 
membrane integrity (Nystrom et al., 2013).  
The results of our proliferation experiments in human primary keratinocytes are consistent 
with the roles of IFNα and IFNλ1 as anti-proliferative agents. Our results show that IFNλ1 
does not have an inhibitory effect on dermal fibroblast proliferation and this may be due to its 
inability to induce STAT1 phosphorylation in these cells. In addition, the anti-proliferative 
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ability of GBP-1 on intestinal epithelial cells has been described (Capaldo et al., 2012) and in 
fibroblasts we failed to detect GBP-1 induction in the context of type III IFN stimulation.  
This study has shown that IFNλR1 is active in human dermal fibroblasts through the 
activation of p38 and ERK pathways. We have shown that MxA induction by IFNλ1 occurs 
through a STAT1-independent pathway and this may also explain the role of this cytokine in 
enhancement of collagen expression and lack of anti-proliferative activity. Of note, IFNλ1 is 
highly expressed in both the scarring and the non-scarring subtype of CLE. Our data 
suggest that IFNλ1 may not be a key molecule in the reduced proliferation seen in dermal 
fibroblasts from discoid CLE patients (Nyberg et al., 2000). Data are lacking so far describing 
the response of tissue cells to type I and III IFN in CLE disease subtypes. 
Egli et al have shown that in CMV treated foreskin derived fibroblast cell lines, IFNλ exerts 
an inhibitory action on IFNα induced antiviral activity (Egli et al., 2014). However, IFNα also 
enhances fibroblasts susceptibitlity to IFNλ. It is thus possible that IFNλ, while important for 
the epidermal antiviral competence (Wolk et al., 2013), may exert important balancing and 
regulatory functions in the dermal compartment. One of the effects could be to counteract 
the type I IFN induced impairment of repair mechanisms.  
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Materials and Methods 
Cytokine and antibodies  
The following cytokines and antibodies were used: Recombinant human (rh) IFNλ1 (100 
ng/ml) was purchased from ebioscience (Hatfield, UK); rhIFNα2a (10 ng/ml; Merck Millipore, 
Merck Serono Ltd, Middlesex, UK), rhTGFβ1 (1 ng/ml or 5 ng/ml; Peprotech EC Ltd, 
London, UK). Rabbit anti-human phospho p38, mouse anti-human phospho ERK, mouse 
anti-human ERK, rabbit anti-human p38, rabbit anti-human phospho STAT1 and rabbit anti-
human STAT1 antibodies were all purchased from Cell signalling Technology (Leiden, The 
Netherlands); rabbit anti-human MxA antibody and mouse anti-human GAPDH antibody 
were purchased from Abcam (Cambridge, UK) and Santa Cruz (Insight Biotechnology Ltd, 
Middlesex, UK) respectively. Rabbit anti-human IFNλR1 was purchased from Sigma Aldrich 
(Dorset, UK). Horseradish peroxidase (HRP) conjugated donkey anti-rabbit and donkey anti-
mouse secondary antibodies were from Santa Cruz. PD98059, U0126 (MEK/ERK inhibitors) 
and SB203580 (p38 inhibitor) were from Cell Signalling Technology. 
Cell Isolation, Culture and Ethics 
Keratinocytes and dermal fibroblasts were derived from anonymised healthy volunteers 
undergoing cosmetic surgery with informed consent, local research ethics approval (Ethical 
Tissue, University of Bradford).  Skin samples were processed on the day of collection. 
Fibroblasts were isolated by placing the trypsinized dermis in a T75 culture flask; ensuring 
the upper layer just below the epidermis adhered firmly to the flask. 10 ml DMEM containing 
10% FBS was carefully added to the flask so as not to allow the dermis to float. Fibroblasts 
explanted after 5 to 7 days. Full details available in supplementary information. 
 
Cell Stimulation 
Keratinocytes or fibroblasts were seeded into 24-well or 6-well and allowed to grow to ~ 80% 
confluency. For keratinocytes, culture medium was replaced with KGM without human 
epidermal growth factor and hydrocortisone (KGM -/-) prior to cell treatment with cytokines. 
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Dermal fibroblasts were starved of serum for 24 hour before treatment in serum-free DMEM. 
For cell tracer proliferation assays, keratinocytes were grown in full KGM and DMEM with 
1% serum for dermal fibroblasts. For inhibition experiments, cells were pre-treated for 1 hour 
with 10 µM SB203580 (Cell signalling), 30 µM PD98059 or 10 µM U0126 (Cell signalling) 
before treatment with IFNα or IFNλ1. Controls included untreated cells and cells treated with 
dimethylsulphoxide vehicle (DMSO), SB203580 or PD98059/U0126 alone for 24 hours. 
Quantitative RT-PCR 
Cultured human keratinocytes or human dermal fibroblasts were either harvested 4, 6 or 24 
hours after treatment with cytokines and total RNA was isolated using Quick mini-prep kit 
(Zymo Research, Cambridge bioscience, Cambridge, UK) according to the manufacturer’s 
protocol. RNA transcription was carried out using first strand cDNA synthesis kit (Fermentas/ 
Thermo Fisher Scientific, Cramlington, UK).  MxA, GBP-1, IFI-16, CXCL9, IFNλR1, Col1A1, 
Col3A1, Col4A2 and Col7A1 QuantiTect primer assays were obtained from Qiagen (Hilden, 
Germany) while U6 primer (forward – 5’ CTCGCTTCGGCAGCACA 3’; reverse-5’ 
AACGCTTCACGAATTTGC 3’) was purchased from Sigma Aldrich, UK. cDNA amplification 
was carried out using QuantiFast qRT-PCR kit (Qiagen) and run in Cfx Connect real-time 
system (Bio-Rad). The following parameters were used: Initial heat activation, 95oC for 5 
minutes; denaturation, 95oC for 10 seconds; combined annealing and elongation, 60oC for 
30 seconds for a 40 cycle run.  Data were analysed using the delta-delta ct method. mRNA 
expression of each gene of interest was normalised to U6 SnRNA housekeeping gene. 
Agarose gel electrophoresis 
qPCR products were run on a 2% agarose gel. Agarose powder was dissolved in Tris, Boric 
acid and EDTA (TBE) buffer. 1µl ethidium bromide was added to the solution. TBE buffer 
was poured into the running tank and qPCR products containing loading dye (30% (v/v) 
glycerol, 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol) were run at 40mA for 
30 minutes. Image was taken under ultraviolet (UV) light. 
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Western blotting 
Keratinocytes and dermal fibroblasts were cultured in 6-well plates. Cells were lysed with 
CelLytic M lysis buffer (Sigma-Aldrich) containing protease inhibitor cocktail (Roche Applied 
Bioscience, Rotkreuz, Switzerland) and phosphatase inhibitor (Thermo Scientific) to. Protein 
concentration was determined by Bradford assay (Thermo Scientific). 30µg of total protein 
was separated according to their molecular weight using 4-20 % gradient mini protean gel 
(BioRad). Proteins were blotted onto 0.2 µm PVDF trans-blot pack (Bio-Rad) and membrane 
blocked in 5% dried semi-skimmed milk in PBS or TBS containing 0.1% Tween-20 (PBST) 
for 1 hour on a shaker at room temperature. Membranes were probed with rabbit anti-human 
pSTAT1 (1:1000), STAT1 (1:1000), phospho p38 (1:1000), mouse anti-human pERK 
(1:2000), p38 (1:1000) or GAPDH (1:3000) in TBST containing 5% bovine serum albumin 
(BSA) overnight at 4oC with gentle shaking. Rabbit anti-human MxA (1:1000) and GAPDH 
were used in 5% milk PBST overnight at 4oC with gentle shaking. Donkey anti-rabbit and 
donkey anti-mouse HRP-conjugated secondary antibodies were used at 1:5000 and 1:3000 
respectively in 5% milk PBST or 0.5% TBST for 1 hour at room temperature. Membranes 
were incubated in enhanced chemiluminiscence (ECL; Bio-Rad) for 2 to 5 minutes at room 
temperature and protein bands were detected using Chemidoc imaging system (Bio-Rad). 
For a repeat Western, membranes were stripped at room temperature for 15 minutes using 
stripping buffer (Thermo scientific) and blocked for 30 minutes prior to probing with primary 
antibody.    
Cell trace proliferation assay 
Human primary keratinocytes and dermal fibroblasts were harvested and resuspended in 
KGM or serum-free DMEM respectively. Cells were then stained with cell trace violet 
(Molecular probes/Life technologies) away from the source of light (2 µl cell trace to 1 million 
cells in 1 ml media). Cells were plated in 6 well plates and were either treated with cytokines 
or untreated for 72 hours.  Some cells were used for the day 0 analysis. For flow cytometric 
analysis, a BD LSRFortessa (BD Bioscience, Oxford, UK) machine was used. Cell 
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proliferation was calculated using ModFit software version 3.2 (Verity Software House, 
Topsham, ME. USA). Full details of proliferation assay available in supplementary 
information online. 
Statistical analysis 
Statistical significance was determined using Mann Whitney test or unpaired t-test. The 
statistical analysis was performed using GraphPad Prism software (GraphPad Software Inc. 
La Jolla, CA, USA). All data are expressed as means ± SEM and values of p < 0.05 were 
considered significant.  *p< 0.05, **p< 0.01. 
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Figure legends 
 
1. IFNλR1 expression and production in human dermal fibroblasts 
Cultured human dermal fibroblasts were either untreated or treated with 10 ng/ml 
IFNα for 4 hours in serum-free medium and mRNA expression was measured using 
quantitiatve real time PCR. (a) Amplification cycles and melting curves (b) qPCR 
products for IFNλR1 and the housekeeping gene U6snRNA on 2% agarose gel are 
shown as a representative experiment out of four independent experiments (c) 
Relative mRNA expression. For statistical analysis, Mann Whitney U test was used to 
compare columns. n=5, values represent mean ± SEM.  *p<0.005, **p<0.01. UT: 
Untreated. 
 
 
2. ISGs expression in human dermal fibroblasts and primary keratinocytes 
Cultured dermal fibroblasts were either untreated or treated with 10 ng/ml IFNα or 
100 ng/ml IFNλ1 for 4 or 24 hours in serum-free medium. Primary keratinocytes were 
treated with the same concentration of cytokines for 6 or 24 hours in KGM without 
EGF and hydrocortisone. mRNA expression of ISGs was measured using qRT-PCR. 
a to d show expression levels as measured in fibroblasts; (a) MxA, 4 hours (b) MxA, 
24 hours (c) GBP-1, 4 hours (d) GBP-1, 24 hours . e to h show expression levels as 
measured in keratinocytes  (e) MxA, 4 hours (f) MxA , 24 hours (g) GBP-1 , 4 hours 
(h) GBP-1, 24 hours. For statistical analysis, Mann Whitney U test was used to 
compare columns. n=5, values represent mean ± SEM.  *p<0.005, **p<0.01. 
 
3. IFNλ1 induced STAT1 and MAPKs phosphorylation fibroblasts and 
keratinocytes 
Cultured human dermal fibroblasts (3a) or primary keratinocytes (3b) were either non 
treated or treated with 10 ng/ml IFNα or 100 ng/ml IFNλ1 for 10, 30 or 60 minutes. 
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Total and phosphorylated p38, ERK and Stat1 along with GAPDH were detected by 
Western Blot.  A representative out of three independent experiments with cells from 
different donors is depicted.  
 
4. Inhibition of MxA production by phospho- p38 and -ERK inhibitors 
Cultured dermal fibroblasts or primary keratinocytes were either untreated or treated 
with MAPK inhibitors or IFNs for 4 and 24 hours and MxA was detected on the 
mRNA level and by Western Blot. (a) MxA mRNA expression after 4 hours of 
treatment; n=3 (b) MxA mRNA expression after 24 hours of treatment; n=3 (c) MxA 
protein expression by IFNλ1 in the presence or absence of MAPK inhibitors in 
fibroblasts. (d) MxA protein expression by IFNα in the presence or absence of MAPK 
inhibitors in fibroblasts (e) MxA protein expression by IFNλ1 and IFNα in human 
primary keratinocytes in the presence or absence of MAPK inhibitors. Figures are 
representative of three independent experiments. SB: SB203580 (p38 inhibitor); U: 
U0126 (MEK/ERK inhibitors).  
 
5. Effect of IFNλ of collagen expression in human dermal fibroblasts 
Cultured dermal fibroblasts were either untreated or treated with 10 ng/ml IFNα, 100 
ng/ml IFNλ1, 5 ng/ml TGFβ1 or combination of IFNλ1 and TGFβ1 for 24 hours. 
mRNA expression of ISGs was measured using qRT-PCR. Depicted is Col1A1 (a) 
expression Col3A1 (b) Col4A2 (c) and Col7A1 (d) expression. For statistical analysis, 
Mann Whitney U test was used to compare columns. n=5, values represent mean± 
SEM.  *p<0.005, **p<0.01. 
 
6. Effects of IFNs on proliferation of skin resident cells 
Human dermal fibroblasts or primary keratinocytes were labelled with cell tracer 
violet. Fibroblasts were resuspended in DMEM containing 1% FBS while 
keratinocytes were resuspended in KGM. Plated cells were either untreated or 
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treated with cytokines. Daughter cell populations of dividing cells were visualised by 
flow cytometric analysis after 72 hours of stimulation. (a) Cell tracer dependent 
fluorescent signal in keratinocytes at 0 hour and after 72 hours of stimulation. (b) 
Graphical representation of percentage proliferation of keratinocytes after 72 hours 
(c) Cell tracer dependent fluorescent signal in fibroblasts at 0 hour and 72 hours after 
stimulation. (d) Graphical representation of percentage proliferation of fibroblasts 
after 72 hours. For statistical analysis, unpaired t test was used to compare columns; 
n=3 and values represent mean± SEM.  *p<0.005, **p<0.01. 
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Figure 2   
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Figure 5 
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          Figure S1 
Differential effects of IFNλ1 and IFNα on dermal fibroblasts monolayer culture 
gap closure 
Monolayer culture of human dermal fibroblasts in 24-well plate was allowed to grow 
to 95% confluence and scratched with p200 (yellow) pipette tip. Cells were either 
untreated or treated with IFNλ1 or IFNα for 48 hours in DMEM without serum Images 
were taken at 0, 24 and 48 hours with Nikon camera under x4 objective. Images are 
representatives of three independent experiments using three different donors. n=3; 
values represent mean ± SEM. 
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           Figure S2 
Proposed schematics of IFNα and IFNλ1 signalling in human dermal fibroblasts 
Upon stimulation of fibroblasts with IFNα, there is mainly the phosphorylation of 
STAT1 and to a lesser extent MAPKs (p38 and ERK). This results in the production 
of MxA and other ISGs. Blocking the MAPKs pathways, may lead to slight reduction 
in MxA production and possibly for other ISGs too. By contrast, stimulation of 
fibroblasts with IFNλ results in phosphorylation of mainly the MAPKs pathway with no 
phosphorylation of STAT1. The phosphorylation of p38 and ERK leads to significant 
production of MxA but not the other ISGs. Blocking these MAPKs pathways results in 
attenuation of MxA production. 
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Supplementary Materials and Methods 
 
Cell Isolation, Culture and Ethics 
Keratinocytes and dermal fibroblasts were derived from healthy volunteers having cosmetic 
surgery with informed consent and local research ethics approval. Skin samples were 
transferred into universal tubes containing transport medium (Dulbecco's modified eagle's 
medium (DMEM; Lonza, Slough, UK) containing 0.5 mg/ml streptomycin and 500 U/ml 
penicillin and 2.5μg/ml amphotericin B (Gibco/life technologies, Paisley, UK) prior to 
processing for cell isolation. Cells were isolated as follows. Skin samples were stripped of fat 
using scissors and were cut up into approximately 1.0 cm2. Cut skin samples were washed 
well in PBS, submerged (epidermis side up) in 0.25% Trypsin (Gibco/life technologies) at 
4°C overnight and subsequently heated at 37°C for 30 minutes to remove epidermal sheets. 
The epidermis was incubated for 5 minutes at 37°C in a water bath in 0.05% Trypsin/EDTA 
(TE; Gibco/life technologies), then vortexed for 1 minute.  Trypsinized cell suspension was 
carefully aspirated and transferred into serum-containing media to neutralise TE and 
subsequently centrifuged for 5 minutes at 1000rpm to pellet cells. The cell pellet was 
resuspended in Keratinocytes growth medium-2 (KGM2; Promocell, Heidelberg, Germany) 
mixed with DMEM containing 10% fetal bovine serum (FBS; PAA/GE healthcare, Little 
Chalfont, UK) in ratio two to one (KGM-2/DMEM; ratio 2:1) and cells were seeded in a T75 
culture flask. This culture medium was replaced with KGM alone after 2 days and 
keratinocytes were cultured to ~80 % confluency at 37oC and 5% CO2 before passage. 
Human dermal fibroblasts were isolated from the dermis by placing the trypsinized dermis in 
a T75 culture flask; ensuring the upper layer just below the epidermis adhered firmly to the 
flask. 10 ml DMEM containing 10% FBS was carefully added to the flask so as not to allow 
the dermis to float. The flask was incubated at 37oC for 1 to 2 weeks with medium change 
every 2 to 3 days until fibroblasts explanted. Fibroblasts were trypsinized and cultured in 
DMEM containing 4.5 g/L glucose and L-Glutamine (Lonza) and supplemented with 10% 
FBS (PAA), 0.1 mg/ml streptomycin and 100 U/ml penicillin. Culture medium was changed 
every 2- 3 days.    
 
Flow cytometric analysis of IL-28Ra (IFNλR1) 
Fibroblasts were washed in ice-cold PBS. For intracellular staining, cells were fixed in 
fixation buffer (Biolegend, Cambridge Bioscience Ltd, Cambridge, UK) for 15 minutes at 
room temperature and permeabilized by washing the cells three times in permeabilization 
buffer (Biolegend). Cells were stained with either 10 µg/ml PE-conjugated anti-IFNλR1 
antibody or PE-conjugated isotype control in permeabilization buffer for 20 minutes at room 
Page 33 of 34 Journal of Investigative Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
temperature. Keratinocytes were resuspended in permeabilization buffer and centrifuged at 
800 x g for a total of 2 washes. Cells were resuspended in cell staining buffer (Biolegend,) 
ready for analysis. For flow cytometry, we used BD LSRFortessa (BD Biosciences, UK). 
Data collected were analysed using Flowjo software (Tree star Inc., USA) 
 
Cell trace proliferation assay 
Human primary keratinocytes and dermal fibroblasts were harvested and resuspended in 
KGM or serum-free DMEM respectively. Cells were then stained with cell trace violet 
(Molecular probes/Life technologies) away from the source of light (2 µl cell trace to 1 million 
cells in 1 ml media). Cells were incubated in a water bath at 37oC for 30 minutes to allow the 
cells to take up the dye. 10 ml KGM or DMEM containing 10% FBS was then added to the 
keratinocytes or fibroblasts respectively and cells were incubated in water bath at 37oC for 
10 minutes in order to remove any unbound dye. Cells were centrifuged at 350 x g for 5 
minutes. Keratinocytes were resuspended in KGM while dermal fibroblasts were 
resuspended in DMEM containing 1% serum. Cells were plated in 6 well plates and were 
either treated with cytokines or untreated for 72 hours.  Some cells were used for the day 0 
analysis. Cells were trypsinized and analysed after 72 hours using flow cytometry. For flow 
cytometric analysis, a BD LSRFortessa (BD Bioscience, Oxford, UK) machine was used. 
Cell proliferation was calculated using ModFit software version 3.2 (Verity Software House, 
Topsham, ME. USA). 
 
Scratch assay 
Human dermal fibroblasts were seeded in 24-well plates and allowed to grow to about 95% 
confluency.  Cells were scratched vertically at the centre of each well with p200 (yellow) 
pipette tip. Cells were washed twice with pre-warmed PBS to remove cell debris and were 
subsequently covered with 500 μl DMEM without serum. Cells were then either untreated or 
treated with 100 ng/ml IFNλ1 or 10 ng/ml IFNα and were allowed to grow for 48 hours while 
monitoring gap closure. Images were taken using a Nikon camera on 4x objective at 0, 24 
and 48 hours after the scratch.      
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